Compare REKR & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REKR | IXHL |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 35.4M |
| IPO Year | 2017 | 2024 |
| Metric | REKR | IXHL |
|---|---|---|
| Price | $0.41 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 50.7K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,234,000.00 | $12,000.00 |
| Revenue This Year | $5.38 | N/A |
| Revenue Next Year | $16.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.16 |
| 52 Week High | $2.60 | $6.39 |
| Indicator | REKR | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 30.21 |
| Support Level | $0.30 | $2.52 |
| Resistance Level | $0.48 | $3.89 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 75.53 | 12.23 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.